OBJECTIVES: This study evaluates reinterventions for degenerated stentless aortic xenografts.
INTRODUCTION
In recent years, stentless xenografts have been increasingly used for aortic valve replacement (AVR) due to their favourable haemodynamic profile [1] [2] [3] . Compared with conventional stented bioprostheses, less structural deterioration was initially expected, but could not be confirmed. Thus, an increase in the number of reoperations after stentless aortic valve implantation can be anticipated, as these valves will soon reach the limits of their durability. Reoperations after stentless AVR have been reported as challenging and are associated with an increased risk of death [4] . After the introduction of catheter-based AVR, valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) has evolved as an additional treatment option. Today, a huge body of literature exists demonstrating the feasibility and success of treating degenerated conventional stented bioprostheses with transcatheter heart valves (THV) [5] [6] [7] [8] [9] [10] [11] . In contrast, less experience is published regarding ViV-TAVI in degenerated stentless aortic valves and these reports frequently deal with degenerated homografts used for aortic root replacement [10, [12] [13] [14] . This study analyses results with redo surgery and ViV-TAVI for treatment of degenerated porcine and pericardial stentless aortic bioprostheses, aiming to define the potential role of ViV-TAVI in this particular setting.
MATERIALS AND METHODS

Patients
We reviewed 52 consecutive patients (77% male, mean age 72.3 ± 9.7 years, 21% > _80 years) who underwent reintervention for a degenerated stentless aortic valve from January 2010 to December 2015 (Ethics Committee approval EA4/095/16).
Other causes for reintervention, e.g. prosthetic valve endocarditis, were excluded. Mean time from the index operation was 10 ± 4.8 years and seven patients (14%) had more than one previous cardiac surgery. The heart team, consisting of an interventional cardiologist, a cardiac surgeon, an echocardiographer and an anaesthetist specialized in cardiothoracic procedures discussed all cases and recommended either reoperation or ViV-TAVI based on clinical presentation, coexisting conditions, anatomical details of the aortic root and the predicted risk. All patients gave written informed consent. Clinical data were assessed before the procedure, at 30 days, at 12 months and yearly thereafter. End-points were defined according to the Valve Academic Research Consortium-2 criteria [15] . At baseline, at Days 5-10, and at follow-up, echocardiographic parameters were assessed using standard techniques.
Surgery
All reoperations were performed via median sternotomy, using an oscillating saw. Cardiopulmonary bypass, installed by cannulation of the ascending aorta, the aortic arch or femoral artery and the right atrium or femoral vein, was used with systemic normothermia or mild hypothermia (32 C) if a patent mammary artery bypass was present. Myocardial protection was achieved with intermittent antegrade blood cardioplegia. Previously implanted stentless valves were either debrided or completely removed. The choice of prosthesis or root replacement was at the discretion of the surgeon. Concomitant procedures were performed according to the standard techniques.
Valve-in-valve transcatheter aortic valve implantation
A standard trans-femoral or transapical TAVI procedure was performed for implantation of balloon-expandable (Edwards Lifesciences Sapien TM , Sapien XT TM ) or self-expanding valves (Medtronic CoreValve TM and CoreValve Evolute TM , Boston Scientific Lotus TM ). The choice for the prosthesis was based on aortic root dimensions determined by multislice computed tomography, angiography and/or echocardiography, the type, size and implantation technique of the existing valve, and the experience of the team performing the implantation. To aid delineation of the target landing zone, either fluoroscopic images coaxial to valvular calcifications or root angiography with the pigtail catheter in the non-coronary sinus in the absence of calcifications was used. In critical cases, balloon inflation and aortic root angiography were performed to exclude potential coronary obstruction before THV implantation. Usually, rapid ventricular pacing (140-180 beats per minute) plus angiography was applied for cardiac output reduction and exact device alignment during deployment. ViV-TAVI cases requiring surgical treatment were analysed as that of the ViV-TAVI group.
Data analysis
Data reporting and statistical analysis followed published definitions and guidelines [15] [16] [17] . Categorical variables are presented as absolute and relative frequencies. For continuous data, means and standard deviations or medians with lower (LQ) and upper quartiles (UQ) were calculated, respectively. Continuous variables were compared between two groups using the Mann-Whitney U-test and categorical data by Fisher's exact test. Survival was analysed using the Kaplan-Meier estimator and sub-groups were compared by the Log-Rank test. Univariate binary regression analysis was used to determine factors of operative mortality. Results are presented as odds ratio with 95% confidence interval. Due to the limited cohort size and the small number of events, no multivariate analysis was performed. A P-value <0.05 was considered to be statistically significant. All the statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Baseline status
Preprocedural characteristics are given in ). In 87%, they were implanted in sub-coronary technique. Overall, 40% of patients were at high risk (EuroSCORE II >10%). Except for age, EuroSCORE II, the incidence of pulmonary hypertension and renal failure (Table 2) , baseline characteristics were similar between ViV-TAVI and surgical patients. Table 2 lists the most important criteria of the heart team decision for redo surgery or ViV-TAVI. During the study period, the relative frequency of ViV-TAVI performed ranged from 20% to 71% per year (Fig. 1) . Detailed procedural data are given in Table 3 . For ViV-TAVI, procedure time and fluoroscopy time was 92 ± 28.6 and 15 ± 8.9 min, respectively. For redo surgery, operation, cardiopulmonary bypass and aortic cross clamp times were 212 ± 59.3, 125 ± 36.3 and 101 ± 25.3 min for isolated procedures and 351 ± 133.0, 229 ± 127.0 and 162 ± 78.0 min for combined procedures, respectively. Valve implantation was successful in all surgical and in 24 (89%) ViV-TAVI cases. Root replacement was performed for aneurysm correction (n = 1), aortic root enlargement (n = 1) and tissue defects caused by excision of the previous prosthesis (n = 4). With ViV-TAVI, the following complications occurred in nine patients (33%): THV malpositioning (n = 3), coronary obstruction (n = 4, Supplementary Table S1), intraprocedural resuscitation (n = 4) and implantation of covered stents for vascular access site complications (n = 2). In 11%, conversion to open surgery was required due to coronary obstruction (n = 2) and failed THV implantation (n = 1). Deployment of more than one THV and postimplant balloon-dilatation was necessary in two and five patients, respectively. There was no instance of annular rupture. One case of aortic dissection occurred during surgery. Analysis of valve sizes and types of reintervention is given in Fig. 2 . No technique was preferentially used for smaller valve sizes (< _21 mm). Table 4 summarizes outcome regarding mortality and morbidity. Overall, there were four procedural deaths, two after surgery (one intractable bleeding and one refractory vasoplegia) and two after ViV-TAVI (one coronary obstruction and one heart failure). Within 30 days, another ViV-TAVI patient died due to coronary obstruction requiring emergency surgery. At 30 days, overall mortality was 10%, similar after surgery and ViV-TAVI (8% vs 11%, P = 1.0). Univariate predictors of early mortality are listed in Table 5 . Between surgical and TAVI patients, there was no significant difference in 30-day morbidity except for the incidence of sepsis (P = 0.02). Median mechanical ventilation time was 5.5 (LQ 3.0, UQ 19.5) h overall and significantly longer after redo surgery [11.0 (LQ 4.5, UQ 42.0) vs 4.0 (LQ 2.0, UQ 12.0) h, P = 0.005]. Although seven surgical patients (28%) required pharmacological circulatory support (inotropes/vasopressors) for >48 h compared with three patients (11%) after ViV-TAVI, this difference was not significant (P = 0.17). Overall, 31 patients (60%) received any transfusion (red blood cells, platelets and/or 
Procedural results
Early outcome
Late outcome
Median follow-up was 21 months (LQ 6.1 months, UQ 40.8 months). It was 96% complete (two patients were lost). Within the first year another four patients died, two after surgery (one ischaemic colitis and one heart failure) and two after ViV-TAVI (one mitral valve endocarditis and one pneumonia). At one year, overall survival was 82.3 ± 5.4%, similar after surgery (83.1 ± 7.7%) and ViV-TAVI (81.5 ± 7.5%, P ¼ 0.76). Within the first year, 13 patients (25%) required rehospitalization. Causes were cardiovascular in six patients (mitral valve endocarditis, pacemaker implantation, implantable cardioverter defibrillator exchange for resynchronization therapy, stroke, transient ischaemic attack and tachyarrhythmia) and non-cardiovascular in seven patients. Although rehospitalization was more frequent after ViV-TAVI (Table 4) , the difference was not significant (P ¼ 0.37). No aortic valve reintervention was necessary. The majority of patients (94%) was in NYHA Class I or II, similar after surgery and ViV-TAVI.
Echocardiographic results
Based on mean indexed effective orifice area (EOAI) of 0.95 ± 0.27 cm 2 /m 2 and mean transvalvular gradient (p mean ) of 14.2 ± 6.8 mmHg, reintervention resulted in good systolic aortic valve function. Figure 3 shows the haemodynamic results in subgroups. Transvalvular gradients were significantly lower with identical or larger size of the new aortic valve, in particular after surgery (right panels of Fig. 3A and C) . Furthermore, lower transvalvular gradients were observed after ViV-TAVI compared with reoperation and with self-expanding compared with balloon-expandable THVs (left panels of Fig. 3A and B) . Six patients presented with p mean > _20 mmHg, one after ViV-TAVI using a balloon-expandable valve and five after reoperation (P ¼ 0.20). In these five cases, the new valve was smaller than the previous stentless valve. According to the accepted threshold of an EOAI <0.65 cm 2 /m 2 , patientprosthesis mismatch occurred in three patients, in two after ViV-TAVI with balloon-expandable valves and in one after reoperation with a conventional stented xenograft (P ¼ 0.58). Overall, no more than trace AR was demonstrated in 39 patients (93%), not different after surgery and ViV-TAVI (100% vs 81%, P ¼ 0.39). Mild and moderate AR was present in two (8%) and three (12%) patients after ViV-TAVI, respectively. There were no cases of severe AR. After ViV-TAVI, no case of device migration was observed.
DISCUSSION
Principal findings
The heart team assigned roughly half of the patients requiring reintervention for degenerated stentless aortic valves each to ViV-TAVI and reoperation. ViV-TAVI patients were older and at higher operative risk than patients undergoing redo surgery. They also presented more frequently with pulmonary hypertension, renal failure and a patent internal mammary artery graft. By comparison, redo surgery was more frequently performed in younger patients and in those requiring concomitant procedures. Despite the significantly higher predicted risk of death, mortality after ViV-TAVI was not significantly different from that after redo surgery. Early mortality (< _30 days) was associated with preoperative renal failure, life-threatening bleeding and necessity for prolonged medical or mechanical circulatory support. After ViV-TAVI, early mortality was in particular associated with intraprocedural coronary obstruction whereas after redo surgery it was associated with more than one concomitant procedure. After surgery, patients required longer respiratory support and more transfusions and developed more frequently sepsis. At follow-up, the majority of patients reported symptomatic improvement regardless of surgical or transcatheter reintervention. Echocardiography demonstrated excellent valve function in most instances, but patient-prosthesis mismatch and paravalvular AR after ViV-TAVI remain a concern.
Risks of reintervention
Reoperations after stentless AVR are considered to be challenging and risky, but the increased risk is primarily associated with prosthetic valve endocarditis, concomitant procedures and reoperation within 1 year [4, 18] . The 30-day mortality rate after redo surgery of 8% reported herein is identical with results of stentless aortic valve reoperation in 40 patients (excluding prosthetic valve endocarditis) from the Toronto group [4] . It is obvious that ViV-TAVI for treatment of degenerated stentless aortic valves is also associated with relevant risk even though no early death was reported in two series [12, 14] . After ViV-TAVI, 30-day mortality was 11% in this study and 7.6% in 459 patients (20.3% stentless xenografts) from the Valve-in-Valve International Registry [10] . Attention to the technique of reintervention, myocardial preservation and haemostasis may prevent complications, in particular bleeding (redo surgery) and coronary obstruction (ViV-TAVI), being most important to reduce the risk of mortality.
Haemodynamic considerations
Surgical as well as transcatheter reintervention re-established aortic valve function. Excellent haemodynamics were achieved with ViV-TAVI, in particular with self-expanding valves, and with reoperation, if the new prosthesis was identical or larger than the previous stentless xenograft (Fig. 3 ). Mild and moderate AR was an issue only after ViV-TAVI. Compared with ViV-TAVI, redo surgery resulted more frequently in a valve diameter reduction compared with the size of the existing stentless valve (Fig. 2B) . In fact, with the use of conventional stented biological or mechanical prostheses for failing stentless xenografts a reduction by approximately two sizes has been reported [19] . It is noteworthy that with implantation of stentless valves as a new substitute size reduction was still an issue in more than 50% of patients (Fig.  2C ). This may explain, why haemodynamic results were not superior with stentless xenografts (Fig. 3C) . Although aortic root replacement could be an alternative avoiding down scaling, its operative risk is not negligible [4, 19] . There was a non-significant trend to use a larger size of self-expanding compared with balloon-expandable THVs for ViV-TAVI in this series, which is in line with recent findings [12, 14] . Duncan et al. [12] implanted self-expanding prostheses (CoreValve TM ) in 22 degenerated stentless aortic valves (77% homografts) and used up to 24% oversized devices in 91% of patients, whereas Bapat et al. implanted balloon-expandable THVs (Sapien TM , Sapien XT TM and Sapien 3 TM ) in 10 degenerated stentless valves (60% homografts) using larger sizes in only 20% [14] . For haemodynamic results and in contrast to redo surgery, there is no reason to choose an oversized THV (Fig. 3B) .
Recommendations for degenerated stentless valves
With ViV-TAVI after stentless AVR, one of the most critical issues is the definition of the type and size of the THV. Several difficulties and potential complications have to be considered: types and implantation techniques (sub-coronary, inclusion cylinder and root replacement) of the existing stentless valve, usually lack of annular calcification, occasionally bulky calcified leaflets, definition of the target landing zone, device malpositioning, migration and embolization, coronary obstruction, and the risk of annular or sinus rupture [8, 9, 14] . As a stent or sufficient calcifications supporting anchoring are usually lacking, an oversized THV is frequently recommended to prevent migration and embolization [12, 20] . For the same reason, some authors prefer selfexpanding valves [12] . An oversized valve implant may cause coronary obstruction. It is important to realize that the geometry of the aortic root is the key factor for this life-threating complication, as (i) the annulus will often be closer to the coronary ostia, in particular after sub-coronary implantation where the proximal suture line more or less presents the annulus and (ii) without a stent, there will be a significant smaller or no gap between the THV and the coronary ostia, especially in case of a cylindrical configuration of the aortic root with a sinus diameter not wider than the diameter of the annulus. In addition, leaflet height, which is typically larger in stentless pericardial valves, and occasional bulky calcifications of the leaflets have to be regarded. All of the four cases of coronary obstruction, which occurred within the first years of our series, involved stentless xenografts implanted with the sub-coronary technique. Three were pericardial valves, but only one THV was oversized. Self-expanding and balloon-expandable THVs were used in two cases each. As stated by others, meticulous planning by preprocedural imaging is essential to control the diametrical risks of coronary obstruction and valve migration [12, 14] . Multislice computed tomography is the most appropriate tool to assess the individual anatomy of the aortic root. Its results have to be included in the heart team discussion enabling a decision for ViV-TAVI-and the most suitable THV-or surgery. Reoperation should still be regarded as standard treatment and certainly preferred if aortic root configuration may complicate TAVI. How the appropriate procedure could be determined by specific criteria has to be assessed in prospective studies. The VIV aortic app, a reference guide in form of a freely downloadable 'app' (www.ubqo.com/viv) should be used very cautiously, as its recommendation is only based on structural features of the implanted bioprosthesis [20] . It is helpful for conventional stented bioprostheses, but rather unsuitable for stentless valves for the aforementioned reasons. Thus, our choice of THV and the recommendation of the 'app' matched in only 39%. As final analysis, aortic root angiography during balloon inflation should be used to visualize potential coronary obstruction before device implantation as the inflated balloon simulates the displacement of the leaflets of the stentless valve by the THV [8, 14] .
CONCLUSION
Reinterventions-redo surgery as well as ViV-TAVI-for degenerated stentless aortic valves are technically challenging and accompanied by a significant periprocedural risk. Early mortality is associated with preoperative renal failure, more than one concomitant procedure, occurrence of complications such as life-threatening bleeding or coronary obstruction, and the necessity for prolonged circulatory support. ViV-TAVI is a reasonable option, especially in elderly patients with high surgical risk due to comorbidity and/or previous coronary artery bypass grafting, but limited success and potential complications have to be considered. Therefore, assessing the individual anatomy of the aortic root is of paramount importance. Redo surgery has its place in younger patients with lower risk, in particular in those requiring concomitant surgical procedures.
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